RxDoctor Payments Data

Annabelle Matias, MD

Internal Medicine · Orange Park, FLNPI 1194709725

Payments from drug & device makers

$87,887in general payments, 2019–2025

Across 175 payments — averaging $502.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$87K
  • Novo Nordisk$526
  • Medtronic$180
  • Recor Medical Inc$162
  • Pfizer$122
  • Boehringer Ingelheim$89
  • plus $69 from 2 others

What the payments were for

  • Food & beverage$1,148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS158$86,739
Novo Nordisk8$526
Medtronic(2 entities)2$180
Recor Medical Inc1$162
Pfizer1$122
Boehringer Ingelheim1$89
Astellas Pharma US Inc2$42
Eisai Inc.2$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,887 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$178,089
Medicare patients
381
Services billed
2,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$93,351
JardianceEmpagliflozin55$60,387
MounjaroTirzepatide57$58,147
EliquisApixaban37$35,723
JanuviaSitagliptin Phosphate43$33,979
LinzessLinaclotide35$29,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$25,650
TrulicityDulaglutide11$16,419
XareltoRivaroxaban17$16,081
MyrbetriqMirabegron11$11,249
EntrestoSacubitril/Valsartan11$10,619
TradjentaLinagliptin16$9,485
Breo ElliptaFluticasone/Vilanterol11$6,660
VascepaIcosapent Ethyl17$5,742
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$5,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$526$93,35180 claims
Boehringer IngelheimJardiance, Tradjenta$89$69,87371 claims
PfizerEliquis$122$35,72337 claims
Astellas Pharma US IncMyrbetriq$42$11,24911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →